What Can We Learn About Pancreatic Adenocarcinoma from Imaging?

被引：0
|
作者：
Rosenthal, Michael [1 ,2 ,3 ]
Schawkat, Khoschy [2 ,3 ]
Muftah, Mayssan [2 ,3 ]
Jajoo, Kunal [2 ,3 ]
机构：
[1] Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2022年 / 36卷 / 05期
关键词：
EUS; Endoscopy; MRI; CT; Resectability; Staging; Imaging; Pancreas; DUAL-ENERGY CT; ENDOSCOPIC ULTRASOUND; DETERMINING RESECTABILITY; DUCTAL ADENOCARCINOMA; COMPUTED-TOMOGRAPHY; BILIARY DRAINAGE; CANCER; DIAGNOSIS; LESIONS; CHEMOTHERAPY;
D O I：
10.1016/j.hoc.2022.06.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PDAC is an aggressive and morbid disease that requires detailed assessments and timely interventions from the imaging members of a multidisciplinary care team. Although CT is the primary modality for detection, staging, and surveillance of PDAC, ERCP, and EUS serve an equally important role in diagnosis and in management of complications. The interpretation of these imaging studies to determine PDAC resectability and treatment pathways should be made as part of a multidisciplinary care discussion involving radiologists, gastroenterologists, surgeons, oncolo-gists, and radiation oncologists.
引用
收藏
页码：911 / 928
页数：18
相关论文
共 50 条
12345